Toggle menu

EMERGE Biobank

Start date:
June 2013
End date:
December 2015
Co-ordinated by:
EMERGE

The Emergency Medicine Annotated Bioresource Consortium (EM-ABC): A pilot and feasability programme

 

 Aim

To develop the infrastructure and pilot a prospective, consecutive, emergency, bioresource that will subsequently be developed for all emergency presentations

Trial Design

A pilot and feasibility programme to establish a bioresource to provide consecutive emergency samples, thus enabling investigation of the development of the acute disease/influence of disease modifiers e.g. treatment and resuscitation.

Chief Investigator

Dr Matt Reed

Local PI

Dr Matt Reed

Research Team

Paul Leonard, Sandra McGillivray, TRAK development team

Dawn Lyster, John Connolly, RIE laboratories

 

Chief Investigator

Dr Matt Reed

Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Local PI

Dr Matt Reed

Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Research Team

Rachel O'Brien

Lead Research Nurse

More EMERGE Trials

To determine the association between high-sensitivity cardiac troponin concentration and obstructive coronary artery disease in patients presenting to the Emergency Department with suspected acute coronary syndrome and cardiac troponin concentration within the normal reference range using CTCA.

Read more

PRECISE-CTCA Trial

To determine the association between high-sensitivity cardiac troponin concentration and obstructive coronary artery disease in patients presenting to the Emergency Department with suspected acute coronary syndrome and cardiac troponin concentration within the normal reference range using CTCA.

Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.

Read more

IONA Study

Identification of Novel Psychoactive Substances (IONA)

The RECOVERY Trial

Randomised Evaluation of COVID-19 Therapy